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Abstract
As the most populated Persian Gulf country in West Asia, methamphetamine use in methadone maintenance
treatment (MMT) is a new health concern in Iran. Methamphetamine use in MMT can originate in methadone
misconceptions or the stimulant effects of methamphetamine use. Several research studies have highlighted the
prevalence of methamphetamine use in Iran and conducting further studies on this issue is being developed. Opiate
use is treated with MMT. But, there is no effective pharmacological treatment for methamphetamine use and
cognitive-behavioral interventions have still remained the best practice.
As a psychostimulant drug, methamphetamine use can lead to poor treatment outcomes or even treatment failure
among patients in MMT. Therefore, the implementation of methamphetamine education and prevention programs in
MMT is required. Prescribing adequate methadone dose and the treatment of comorbidities as well as, doing a series
of activities outside treatment is underscored. Methamphetamine use has a chronic nature and methamphetamine
treatment is a long-term procedure with a high rate of relapse. Therefore, the implementation of long-term
motivational interviewing, teaching necessary skills to prevent relapse and case management is highlighted. A long-
term collaboration between treatment teams, patients and their families is suggested to manage methamphetamine
use in MMT.
Editorial
Methamphetamine use is a current global health concern
[1]. Iran (e.g., Persia or the land of Persians) is an upper
middle-income country with a population of 78 million in
the west of Asia. The history of drug use in the Persian so-
ciety dates back to the time of its Mesopotamia-related
civilization and the Persian Empires. The use of some
plants with euphoric effects was common for religious
ceremonies at the time of Zoroaster and Cyrus the Great,
the Persian prophet and king in Persia. Because of
Afghanistan, the main global opium cultivator in the
neighborhood of Iran, Afghan opiates typically opium and
opium residues have been always the traditional drugs of
use in Iran [2]. Nonetheless, in recent years, a manifest
transition from the traditional pattern of opium use
to impure methamphetamine use has been reported
in the Persian society [3, 4]. Before 2005, methampheta-
mine use was rare in Iran [2, 3]. High purity and expensive
methamphetamine was first imported from Southeast
Asia. But after a few years, its production was illegally ini-
tiated with inexpensive ingredients in clandestine labora-
tories in Iran. This issue became a main reason for
methamphetamine use in the Persian society [2, 3].
In the rapidly developing and competitive environment
of Iran, when the new highly educated generation seeks
for ambitious social and economic status, the stimulant
effects of the Persian methamphetamine such as physical
energy and wakefulness may be primarily attractive
[5, 6]. Nonetheless, this transition has been primarily
reported in opiate users in the society and MMT across
the country [5, 6]. Literature is not well-documented on
this issue. But, Iran is an exceptional country in the region
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that has increasingly improved its research system [7].
Therefore, conducting studies of the Persian metham-
phetamine use in MMT is being developed. For example;
a study of 150 patients in MMT at Iranian National
Center for Addiction Studies in Tehran found that
15 %, 24 %, and 12 % of the patients were metham-
phetamine users while in treatment in months one,
three, and six, respectively [8]. A study at the metha-
done clinic of a central hospital in Zahedan found
that methamphetamine use dramatically increased
among clients from 6 % in 2009 to almost 20 % in
2011 [9]. In 2013, a survey of 7,342 men and women
(82.5 % vs. 17.5 %) at methadone clinics and centers
in the Northern Khorasan province found that 2.8 %
of the patients were methamphetamine users in
MMT [10]. A study of 120 clients at several metha-
done clinics in Tehran found that 64.7 % of clients
smoked methamphetamine after six months of metha-
done treatment [11]. A recent study of oral and den-
tal health of 95 women at women-only methadone
centers in Tehran found that the mean age of the
sample was 38 years old. The mean duration of drug
dependence was 11.6 years. The most common drug
of use was methamphetamine (71.7 %), and the most
common route of methamphetamine administration
was smoking [12].
Methamphetamine use in MMT has serious health im-
plications and can originate in different reasons [1].
Some recent research studies show that methampheta-
mine use in MMT in Iran is associated with methadone
misconceptions, relieving the side effects of methadone
use such as depression and poor sexual performance, in-
creasing physical energy, concentration, attention span,
socializing with others [6], pleasure and experience seek-
ing [13]. Methamphetamine use in MMT can be associ-
ated with other factors. A study of 150 women at a
women-only methadone center in Tehran found that the
median age of the sample was 34 years. Women were
poly smokers of opiates with methamphetamine. Overall,
51.3 % of them had positive urine specimens for meth-
amphetamine use in MMT. Among the women who had
positive urine specimens, long duration of poly use of
opiates and methamphetamine, poor family support,
poor motivations to change methamphetamine use, poor
participation in counseling sessions, depression, an in-
ability to cope with everyday life pressures and poor
skills to cope with methamphetamine were associated
with methamphethamine use [14].
Opiate use is treated with MMT. But, methampheta-
mine use has no approved pharmacological treatment in
the world [15]. The main treatment approach is long-term
cognitive-behavioral treatment (CBT) [16] which may not
be always appealing to methamphetamine users in MMT.
Therefore, the implementation of methamphetamine
education and prevention programs in MMT should be a
health priority for treatment teams at methadone centers.
The side effects of methadone use and/or methadone mis-
conceptions should be gradually explained and settled
down by treatment teams at methadone centers. The col-
laboration of medical doctors with psychologists at the
centers is required to eliminate these problems. Meth-
amphetamine use in MMT may lead to treatment failure
and the sudden interruption of methadone program with
no definite positive outcome. Therefore, the simultaneous
provision of psychological interventions such as CBT and
prescribing adequate methadone dose are primarily
underscored. Adequate physical exercise, having an appro-
priate nutrition, a practical program for daily activities and
strong family relationships and support should be simul-
taneously consulted with clients and their families. Psychi-
atric and physical comorbidities should be specifically
addressed. Comorbidities such as decreased sexual desire
and depression may increasingly facilitate methampheta-
mine use in MMT. Most of the clients may not report
craving for methamphetamine use in MMT because using
regular methadone dose could prevent drug craving in
general. Such clients may use methamphetamine because
of their former addictive life styles, peer pressure and liv-
ing in environments with an easy access to inexpensive
methamphetamine. Methamphetamine use has a chronic
nature and methamphetamine treatment is a long-term
procedure with a high rate of relapse [2–4]. Therefore, the
implementation of long-term motivational interview-
ing and teaching necessary skills to prevent relapse and
case management is suggested.
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